Table 3.
Multivariate analysis for survival of patients in the training cohort and validation cohort
| Variables | OS | RFS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Training cohort | ||||
| TNM stage (III/II/I) | 1.448 (1.180–1.777) | <0.001 | 1.359 (1.132–1.631) | 0.001 |
| Tumor differentiation (poor/well to moderate) | 1.319 (1.010–1.723) | 0.042 | NA | NA |
| Vascular invasion (Yes/no) | 1.363 (1.002–1.854) | 0.048 | NA | NA |
| CA19-9 (>37/≤37 U/mL) | 1.380 (1.013–1.880) | 0.041 | 1.433 (1.075–1.909) | 0.014 |
| Chemotherapy (yes/no) | 0.493 (0.368–0.660) | <0.001 | 0.751 (0.569–0.992) | 0.044 |
| NLR (>2.24/≤2.24) | 1.167 (0.835–1.630) | 0.366 | 1.407 (1.039–1.905) | 0.027 |
| PLR (>100.25/≤100.25) | 1.076 (0.743–1.557) | 0.698 | 1.121 (0.792–1.586) | 0.521 |
| SII (>330.30/≤330.30) | 0.975 (0.638–1.490) | 0.907 | 0.922 (0.624–1.362) | 0.683 |
| SIRI (>0.69/≤0.69) | 1.655 (1.130–2.425) | 0.010 | 1.463 (1.037–2.063) | 0.030 |
| Validation cohort | ||||
| TNM stage (III/II/I) | 1.472 (1.139–1.902) | 0.003 | 1.437 (1.163–1.776) | 0.001 |
| Vascular invasion (Yes/no) | NA | NA | 1.276 (0.935–1.742) | 0.124 |
| Perineural invasion (Yes/no) | 1.589 (0.985–2.564) | 0.058 | NA | NA |
| CA19-9 (>37/≤37 U/mL) | 1.385 (0.882–2.175) | 0.157 | 1.332 (0.932–1.904) | 0.116 |
| Chemotherapy (Yes/no) | 0.457 (0.310–0.674) | <0.001 | 0.731 (0.515–1.040) | 0.081 |
| NLR (>2.24/≤2.24) | 1.142 (0.739–1.765) | 0.550 | 0.993 (0.691–1.428) | 0.971 |
| SII (>330.30/≤330.30) | 0.904 (0.566–1.443) | 0.672 | 1.063 (0.733–1.542) | 0.747 |
| SIRI (>0.69/≤0.69) | 2.114 (1.326–3.370) | 0.002 | 1.766 (1.209–2.578) | 0.003 |
Abbreviations: OS overall survival; RFS, recurrence-free survival; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; NA, not adopted.